Entera Bio (ENTX) EBITDA Margin (2021 - 2025)

Entera Bio has disclosed EBITDA Margin across 4 years of filings, most recently posting 6102.38% for Q1 2025.

• Quarterly EBITDA Margin changed N/A year-over-year to 6102.38% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 27600.0% (down 2227017.0% YoY) and the FY2025 annual result came in at 27450.0%, down 2215442.0% from the prior year.
• EBITDA Margin slipped to 6102.38% in Q1 2025, from 2908.54% in the prior quarter.
• Over five years, EBITDA Margin peaked at 1489.81% in Q1 2021 and troughed at 35812.5% in Q3 2022.
• A 4-year average of 8282.43% and a median of 4749.68% in 2022 frame the typical range for EBITDA Margin.
• Biggest YoY gain for EBITDA Margin was 414990 bps in 2022; the steepest drop was 3351250 bps in 2022.
• Tracing ENTX's EBITDA Margin over 4 years: stood at 2477.58% in 2021, then tumbled by 785 bps to 21914.29% in 2022, then soared by 87 bps to 2908.54% in 2024, then sank by 110 bps to 6102.38% in 2025.
• Business Quant data shows ENTX's EBITDA Margin at 6102.38% in Q1 2025, 2908.54% in Q4 2024, and 7142.86% in Q3 2024.